Literature DB >> 30981590

Assessing the Feasibility and Accuracy of High-resolution Microultrasound Imaging for Bladder Cancer Detection and Staging.

Alberto Saita1, Giovanni Lughezzani1, Nicolò Maria Buffi2, Rodolfo Hurle1, Luciano Nava3, Piergiuseppe Colombo4, Pietro Diana5, Vittorio Fasulo5, Marco Paciotti5, Grazia Maria Elefante4, Massimo Lazzeri1, Giorgio Guazzoni5, Paolo Casale1.   

Abstract

BACKGROUND: Magnetic resonance imaging (MRI) has been proposed as a staging tool for bladder cancer (BC), but its use has been limited by its high costs and limited availability. Microultrasound (mUS) is a novel technology capable of providing high-resolution images of the prostate.
OBJECTIVE: To test the feasibility of high-resolution mUS in patients diagnosed with BC and its ability to differentiate between non-muscle-invasive BC (NMIBC) and muscle-invasive BC (MIBC). DESIGN, SETTING, AND PARTICIPANTS: This is an observational prospective study performed in 23 patients with a diagnosis of primary BC scheduled for an endoscopic treatment. SURGICAL PROCEDURE: Micro-US was performed before transurethral resection of bladder tumor using the ExactVu system with an EV29L 29-MHz side-fire transducer (Exact Imaging, Markham, Canada). MEASUREMENTS: The endpoints were to test the feasibility, describe the normal bladder wall anatomy, identify the lesions, and compare the mUS findings with the histopathological results. RESULTS AND LIMITATIONS: Micro-US was accurate in differentiating the three layers of the bladder wall in all cases. Bladder cancers were clearly identified as heterogeneous structures protruding from the normal bladder wall. In 14 cases the lesions appeared confined to the lamina propria, and in all cases NMIBC was confirmed by the final pathological report. In the other patients, the lesions seemed to extend into the muscular layer, but MIBC was confirmed in five out of seven cases (71.4%) from the pathologist. The small sample size was the main limitation of the current study.
CONCLUSIONS: Our findings showed that mUS is able to differentiate the bladder wall layers and identify the bladder cancer stage. Further studies with a larger population and imaging correlation with MRI are warranted before its introduction in clinical practice. PATIENT
SUMMARY: In this report, a new imaging technique was tested for the characterization of bladder cancer. Microultrasound appears to be feasible and capable of discriminating between superficial and invasive tumors.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Bladder cancer; High-resolution ultrasound; Microultrasound; Muscle-invasive bladder cancer; Non-muscle-invasive bladder cancer; Staging

Mesh:

Year:  2019        PMID: 30981590     DOI: 10.1016/j.eururo.2019.03.044

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  4 in total

1.  High-resolution microultrasound imaging for bladder cancer: the birth of a new diagnostic tool?

Authors:  Marta Bottero; Emanuele Alì; Chiara Demofonti; Andrea Lancia; Riccardo Santoni; Cynthia Aristei; Gianluca Ingrosso
Journal:  Transl Androl Urol       Date:  2019-12

2.  Xpert Bladder Cancer Monitor May Avoid Cystoscopies in Patients Under "Active Surveillance" for Recurrent Bladder Cancer (BIAS Project): Longitudinal Cohort Study.

Authors:  Vittorio Fasulo; Marco Paciotti; Massimo Lazzeri; Roberto Contieri; Paolo Casale; Alberto Saita; Giovanni Lughezzani; Pietro Diana; Nicola Frego; Pier Paolo Avolio; Piergiuseppe Colombo; Grazia Maria Elefante; Giorgio Guazzoni; Nicolò Maria Buffi; Michael Bates; Rodolfo Hurle
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

Review 3.  The Role of Imaging in Bladder Cancer Diagnosis and Staging.

Authors:  Samuel J Galgano; Kristin K Porter; Constantine Burgan; Soroush Rais-Bahrami
Journal:  Diagnostics (Basel)       Date:  2020-09-16

4.  Feasibility of [68Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma.

Authors:  Vera Wenter; Alexander Kretschmer; Lena M Unterrainer; Simon Lindner; Lennert Eismann; Jozefina Casuscelli; Franz-Josef Gildehaus; Vinh Ngoc Bui; Nathalie L Albert; Adrien Holzgreve; Leonie Beyer; Andrei Todica; Matthias Brendel; Clemens C Cyran; Alexander Karl; Christian G Stief; Stephan T Ledderose; Marcus Unterrainer; Peter Bartenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-24       Impact factor: 10.057

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.